SCHEMBL6850768

SCHEMBL6850768

O=C(NC1CCc2[nH]cnc2C1)c1ccc(Cl)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
NPC1 O15118 2/20 0.43
RAB9A P51151 1/20 0.43
CHRNA7 P36544 2/20 0.43
ADRA2A P08913 2/20 0.42
HRH1 P35367 2/20 0.42
HTR2B P41595 2/20 0.42
MCHR1 Q99705 2/20 0.42
HDAC8 Q9BY41 2/20 0.41
EPHX1 P07099 1/20 0.40
ADRA1A P35348 1/20 0.40
CA12 O43570 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
CA7 P43166 1/20 0.40
CA14 Q9ULX7 1/20 0.40
LMNA P02545 1/20 0.40
GAA P10253 1/20 0.39
HTR3E A5X5Y0 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL6851386 0.99 MEN1 (0.43) MEN1KMT2ANPC1RAB9ACHRNA7
SCHEMBL7094424 0.88 MTNR1A (0.49) MEN1KMT2ANPC1RAB9AADRA1A
SCHEMBL6849680 0.83 LMNA (0.56) KMT2ANPC1RAB9ALMNA
SCHEMBL6851396 0.82 MCHR1 (0.46) NPC1RAB9AMCHR1EPHX1DRD4
SCHEMBL6846858 0.81 LMNA (0.43) MEN1KMT2AEPHX1LMNAHDAC6
SCHEMBL6846975 0.81 POLB (0.50) NPC1RAB9AHDAC8LMNAGAA
SCHEMBL6846977 0.81 POLB (0.50) NPC1RAB9AHDAC8LMNAGAA
SCHEMBL6846909 0.79 LMNA (0.45) HDAC8EPHX1LMNAHDAC6
SCHEMBL6851425 0.79 MGLL (0.42) MEN1KMT2AADRA2AHTR2BADRA1A
Hydrochloric Acid SCHEMBL7096357 0.78 LMNA (0.44) HDAC8EPHX1LMNAHDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6756384-B2 TREATMENT OF DISEASES AND DISORDERS RELATED TO THE HISTAMINE H3 RECEPTOR. NOVO NORDISK A/S (DK) 2004-06-29 US disclosed
US-20030135056-A1 Imidazole compounds HIGH POINT PHARMACEUTICALS, LLC 2003-07-17 US disclosed
US-6437147-B1 FOR THERAPY OF DISEASES OF CENTRAL NERVOUS SYSTEM, PERIPHERAL NERVOUS SYSTEM, CARDIOVASCULAR SYSTEM, PULMONARY SYSTEM, GASTROINTESTINAL SYSTEM AND ENDOCRINOLOGICAL SYSTEM NOVO NORDISK (DK) 2002-08-20 US disclosed
US-20020058659-A1 Imidazole compounds HIGH POINT PHARMACEUTICALS, LLC 2002-05-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030135056-A1 Imidazole compounds HRH3, HRH4, HRH2 MEN1 1139/4885KMT2A 300/4885NPC1 866/4885
US-20020058659-A1 Imidazole compounds HRH3, HRH4, HRH2 MEN1 1139/4885KMT2A 300/4885NPC1 866/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.